BioStock: SynAct Pharma announces change in management

The biotech company SynAct Pharma has important clinical data coming in 2023 and recently expanded its portfolio with the acquisition of TXP Pharma. SynAct is now making a switch in management to focus more on business development. Current Chairman Torbjørn Bjerke will take over as CEO as Jeppe Øvlesen steps down. Synact also proposes changes in the board with the current member Uli Hacksell as the new Chairman and Thomas von Koch as a board member.

Read the article about SynAct Pharma at biostock.se:

https://www.biostock.se/en/2023/04/synact-pharma-announces-change-in-management/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se